First US patient treated with Aqua Medical's investigational endoscopic therapy for type 2 diabetes signals potential breakthrough in minimally invasive metabolic treatment
Executive summary: Aqua Medical treated the first U.S. patient with its investigational endoscopic therapy for type 2 diabetes at UNC Health under an FDA IDE. The treatment demonstrates feasibility of a novel minimally invasive metabolic intervention that could complement or replace pharmacologic diabetes management.
Who is involved: Aqua Medical, Inc.; UNC Health; U.S. Food and Drug Administration (FDA); the patient receiving the procedure.
Likely next: Expansion of the study to additional U.S. sites later in 2026; submission of pivotal trial data to the FDA; early discussions with payers about coverage and reimbursement.
Aqua Medical announced that it successfully treated the first U.S. patient with its investigational through-the-scope endoscopic metabolic restoration therapy at UNC Health. The procedure, conducted under an FDA-authorized investigational device exemption, aims to improve glycemic control via a minimally invasive endoscopic approach. This milestone marks the initial clinical validation of the technology in the United States and could influence future diabetes treatment pathways.
Timeline
- — Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy (PR Newswire)
Analysis — what this means
Likely next events
- FDA review of pivotal trial data expected Q1 2027
- Expansion of the endoscopic therapy study to two additional U.S. medical centers by December 2026
- CMS to begin coverage deliberation for endoscopic metabolic therapies in mid‑2027
- Aqua Medical to announce a strategic partnership with a major diabetes device company within the next three months
Sectors affected
- Medical devices – endoscopy
- Diabetes care and therapeutics
- Health insurance and reimbursement
Regulatory implications
- FDA’s Investigational Device Exemption (IDE) pathway guiding the current trial
- Potential 510(k) or PMA submission pending trial outcomes
- CMS National Coverage Determination process for novel metabolic endoscopic procedures
Historical parallels
- FDA approval of endoscopic sleeve gastroplasty for obesity (2020)
- Early‑feasibility trial of duodenal mucosal resurfacing for type 2 diabetes (2018)